Research, Development, Innovation

Research at Bayer

Innovation and the skills of our employees form the basis for our success as a company. We drive innovation by continuously developing new molecules, technologies and business models in our research centers, investing in research and development projects, supporting the development of our employees and expanding our activities through acquisitions or collaborations with external partners. Strengthening our innovative capability enables us to address the challenges of our time and achieve profitable corporate growth.

Research at Bayer

In 2014 a total of €3,574 million (2013: €3,406 million) was spent on research and development. This was equivalent to 8.5% (2013: 7.9%) of sales. The number of employees working in research and development worldwide was approximately 14,000.

As well as investing in research and development, Bayer promotes an innovation culture based on openness to new approaches and internal interdisciplinary cooperation. We are building a national and international network of outstanding scientists to further increase our expertise and extending this network through collaborations with external partners.


Our collaborations and alliances with leading universities, public research institutes and partner companies are supplemented by incubators, crowdsourcing and science hubs in Asia and the United States to tap into external innovative potential using the open innovation approach. Some of our collaborations are supported by public funding.

Innovation Areas of the Bayer Group

Research beyond Borders

Strengthening Research in the Life Sciences
Bayer is the only global company simultaneously researching improvements in human, animal and plant health. Systematic and intensive collaboration among researchers from both Life Science subgroups is providing new impetus. In this context, researchers from HealthCare and CropScience are collaborating on projects involving central biological processes such as gene regulation or energy metabolism. Such projects are aimed at developing a better understanding of diseases, deciphering mechanisms of action, personalizing therapies or explaining resistance mechanisms. The joint use of technology platforms is being expanded. The joint use of technology platforms is being expanded. These projects have been supported since 2012 by Bayer’s internal “Life Sciences Fund” and are mostly implemented together with external partners.

Research and Development Expenses 2014

Research Spending

Reliable, global protection of intellectual property rights is essential for an innovation company like Bayer. At the end of 2014, we owned approximately 68,200 valid patent applications and patents worldwide relating to some 8,300 protected inventions.

Research and Development Expenses 2014

Research and Development Expenses 2014

Research and Development expenses 2014
by subgroup in %

Research and Development expenses 2014
by subgroup in EUR million

Research and Development Expenses 2014
Last updated: June 18, 2015 Copyright © Bayer AG
http://www.bayer.com